NeOnc Technologies Holdings, Inc. - Common Stock (NTHI)
4.9000
-0.0700 (-1.41%)
NASDAQ · Last Trade: Jul 31st, 7:09 PM EDT
Detailed Quote
Previous Close | 4.970 |
---|---|
Open | 4.750 |
Bid | 4.600 |
Ask | 5.130 |
Day's Range | 4.545 - 5.170 |
52 Week Range | 3.200 - 25.00 |
Volume | 69,173 |
Market Cap | 93.23M |
PE Ratio (TTM) | -2.333 |
EPS (TTM) | -2.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 486,810 |
Chart
News & Press Releases
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S.
Via ACCESS Newswire · July 30, 2025
CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features cutting-edge 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug discovery and high-throughput screening of brain-targeted therapies. These assets will be integrated into NeOnc’s expanding IP platform and will be also part of NeOnc’s Middle East partnership with Quazar Investment Group, which is designed to help drive global innovation and clinical trial execution across the GCC region.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 30, 2025
Via Benzinga · July 30, 2025
Via Benzinga · July 29, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · July 29, 2025
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 29, 2025
CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 28, 2025
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 23, 2025
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on YouTube.com/@Floorstocks. The interview will air live today at 11:00 a.m. ET.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 23, 2025
CALABASAS, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: execution and transfer of a Sub-License Agreement from NeOnc to its Abu Dhabi onshore operating subsidiary, NuroCure. The Sub-License covers the UAE and the wider GCC and MENA region with respect to NEO100 and NEO212, pursuant to NeOnc’s license from USC Stevens Center for Innovation.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 22, 2025
Via Benzinga · July 14, 2025
Via Benzinga · July 10, 2025
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc’s Board of Directors.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 10, 2025
CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 9, 2025
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · July 8, 2025
Via Benzinga · July 3, 2025

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · June 6, 2025
Via Benzinga · April 30, 2025
Via Benzinga · April 23, 2025
Via Benzinga · April 23, 2025
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position --
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · April 15, 2025
-- Trial Read-Out Data Expected in Early 2026 --
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · April 14, 2025
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company’s strategic and clinical initiatives.
By NeOnc Technologies Holdings, Inc. · Via GlobeNewswire · April 10, 2025